RxDoctor Payments Data

Vanessa Levine, NP

Nurse Practitioner · Cape Coral, FLNPI 1114483906

Payments from drug & device makers

$3,914in general payments, 2019–2025

Across 114 payments — averaging $34.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merz North America, Inc.$1K
  • AbbVie$533
  • Johnson & Johnson$398
  • Galderma Laboratories, L.p.$395
  • Amgen$238
  • Sun Pharmaceutical Industries Inc.$217
  • plus $1K from 14 others

What the payments were for

  • Travel & lodging$51513%
  • Food & beverage$3,09079%
  • Education$3108%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,914 in reported general payments places this provider in the 90th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$76,341
Medicare patients
375
Services billed
1,176

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa14$282,169
OtezlaApremilast42$201,126
Taltz AutoinjectorIxekizumab26$175,075
Cosentyx Sensoready (2 Pens)Secukinumab15$108,230
Dupixent PenDupilumab12$45,740
ZoryveRoflumilast11$9,676
Clobetasol Propionate206$9,058
Fluorouracil60$5,120
Ketoconazole223$3,376
Tacrolimus16$2,769
Metronidazole54$2,599
Triamcinolone Acetonide114$1,736
Clindamycin-Benzoyl PeroxideClindamycin Phos/Benzoyl Perox13$1,605
Doxycycline Hyclate58$1,478
Betamethasone Valerate56$1,416

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$238$201,12642 claims
Arcutis Biotherapeutics, Inc.Zoryve$71$9,67611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Cape Coral

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →